Esa Medika (EMMI) to Debut on IDX, Check Its Prospects Here

JAKARTA. PT Esa Medika Mandiri, a company engaged in the wholesale trading of laboratory, pharmaceutical, and medical devices for humans, is ready to debut on the Indonesia Stock Exchange (IDX) through an initial public offering (IPO). The prospective issuer, with the stock code EMMI, is offering 522,857,000 shares, equivalent to 30% of the company’s total issued and fully paid-up capital after the IPO. During the initial offering period, or bookbuilding, EMMI has set a price range of Rp 446–Rp 515 per share. Thus, EMMI could potentially raise fresh funds of up to Rp 269.27 billion. Barring any obstacles, EMMI will list on the stock exchange on 8 July 2026.

Examining EMMI’s Prospects

Fundamentally, PT Esa Medika Mandiri operates in a sector with fairly good medium- to long-term growth prospects, namely the distribution and manufacturing of medical devices. The national medical device industry continues to be driven by increased government health spending, the expansion of healthcare facilities, the National Health Insurance (JKN) programme, and efforts to boost the use of domestic products (TKDN). The prospectus also states that the Indonesian medical device market is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 8.68% until 2030. EMMI has also obtained TKDN certification, which can be an added value in participating in government procurement. During the 2022–2025 period, the company recorded project wins of more than Rp 750 billion. Its financial performance also shows quite significant improvement. 2025 sales grew 18.1%, while net profit increased 188.2% compared to the previous year. Profitability ratios such as Return on Assets (ROA) and Return on Equity (ROE) also rose, accompanied by a decline in leverage, indicating an increasingly healthy capital structure.

Considerations for Investors

In addition, there are several aspects that deserve investors’ attention before making an investment decision. Investors can observe the still substantial potential of the national medical device market. Increased health spending, modernisation of healthcare facilities, and the national health system transformation programme have the potential to drive long-term industry growth. It is also important for investors to look at the company’s competitive position within its industry. Esa Medika has more than two decades of experience, a distribution network, and TKDN certification, which can be an added value in capturing growing market opportunities. Investors can also scrutinise the use of IPO proceeds and see whether the funds support business expansion, increased business capacity, or strengthening of the company’s capital structure. “Overall, the factors to be observed are not only the growth of the health sector, but also the company’s ability to convert these industry opportunities into sustainable revenue and profit growth after becoming a public company.”